EcoDrugPlus

Toll Like Receptor 4

Ensembl ID : ENSOCUG00000002216
Gene Symbol: TLR4
3 Cross references
127 Possible Orthologues:

Toll Like Receptor 8

Ensembl ID : ENSOCUG00000012701
Gene Symbol: TLR8
3 Cross references
200 Possible Orthologues:

Toll Like Receptor 9

Ensembl ID : ENSOCUG00000024735
Gene Symbol: TLR9
2 Cross references
82 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSOCUG00000017485
Gene Symbol: TAAR1
2 Cross references
602 Possible Orthologues:

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSOCUG00000016292
Gene Symbol: TGFBR1
2 Cross references
230 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSOCUG00000021250
Gene Symbol: TRPA1
2 Cross references
226 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSOCUG00000002047
Gene Symbol: TRPM8
3 Cross references
158 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSOCUG00000012228
Gene Symbol: TRPV1
3 Cross references
134 Possible Orthologues:

Transthyretin

Ensembl ID : ENSOCUG00000017348
Gene Symbol: TTR
3 Cross references
163 Possible Orthologues:

Tubulin Alpha 1c

Ensembl ID : ENSOCUG00000028032
Gene Symbol: TUBA1C
2 Cross references
116 Possible Orthologues:

Tubulin Alpha 3c

Ensembl ID : ENSOCUG00000034139
Gene Symbol: TUBA3C
2 Cross references
185 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSOCUG00000026994
Gene Symbol: TUBA4A
3 Cross references
224 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).